WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201922
Description: Balamapimod, also known as MKI-822, is a Ras/Raf/MEK inhibitor. Balamapimod, may be potentially useful for the treatment or inhibition of certain diseases that are the result of deregulation of Ras/Raf/MEK protein kinases. In addition, Balamapimod may be also useful for the treatment and inhibition of stroke, osteoporosis, rheumatoid arthritis and other inflammatory disorders, as well as polycystic kidney disease and colonic polyps.
MedKoo Cat#: 201922
Name: Balamapimod (MKI-833)
Chemical Formula: C30H32ClN7OS
Exact Mass: 573.20776
Molecular Weight: 574.14
Elemental Analysis: C, 62.76; H, 5.62; Cl, 6.17; N, 17.08; O, 2.79; S, 5.58
Synonym: MKI-833; MKI 833; MKI833; Balamapimod
IUPAC/Chemical Name: 4-((3-chloro-4-((1-methyl-1H-imidazol-2-yl)thio)phenyl)amino)-6-methoxy-7-(4-(pyrrolidin-1-yl)piperidin-1-yl)quinoline-3-carbonitrile
InChi Key: CVAKNHIXTWLGJO-UHFFFAOYSA-N
InChi Code: InChI=1S/C30H32ClN7OS/c1-36-14-9-33-30(36)40-28-6-5-21(15-24(28)31)35-29-20(18-32)19-34-25-17-26(27(39-2)16-23(25)29)38-12-7-22(8-13-38)37-10-3-4-11-37/h5-6,9,14-17,19,22H,3-4,7-8,10-13H2,1-2H3,(H,34,35)
SMILES Code: N#CC1=C(NC2=CC=C(SC3=NC=CN3C)C(Cl)=C2)C4=CC(OC)=C(N5CCC(N6CCCC6)CC5)C=C4N=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not soluble in water.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 574.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Olszewski, John D.; Berger, Dan M.; May, Michael K. Carbon-14 labelling of 3-cyanoquinolines. Journal of Labelled Compounds and Radiopharmaceuticals (2007), 50(5-6), 578-579. CODEN: JLCRD4 ISSN:0362-4803. CAN 149:128783 AN 2007:1003855 CAPLUS
2. Olszewski, John David; May, Michael K.; Berger, Dan Maarten. Process for preparation of radiolabeled 3-cyanoquinoline derivatives. U.S. Pat. Appl. Publ. (2007), 29pp. CODEN: USXXCO US 2007208164 A1 20070906 CAN 147:322859 AN 2007:993243 CAPLUS
3. Berger, Dan Maarten; Powell, Dennis William; Wu, Biqi. Preparation of 3-quinolinecarbonitrile protein kinase inhibitors for treating various diseases. U.S. Pat. Appl. Publ. (2005), 42 pp. CODEN: USXXCO US 2005187247 A1 20050825 CAN 143:248299 AN 2005:904344 CAPLUS.